Business, energy, technology, markets and global industry news from Business News Today

autoimmune diseases

PharmaDeviceNews autoimmune diseases
Sail Biomedicines’ in vivo CAR-T collaboration with Johnson & Johnson highlights growing investment in RNA-based immune-cell therapies for autoimmune diseases. Representative image.
Pharma & Biotech

Why Johnson & Johnson is staking $785m on Sail’s in vivo CAR-T platform before human trials

Johnson & Johnson backs Sail Biomedicines’ in vivo CAR-T platform with $785 million in initial payments and a $2.58 billion buyout option.

Read More
Representative image: Advanced antibody and immune-cell research highlights TRexBio’s TRB-071 CD30 agonist programme and Eli Lilly and Company-partnered TRB-051 as both candidates progress in autoimmune disease development.
Pharma & Biotech

Lilly advances TRB-051 in lupus as TRexBio unveils the mechanism behind TRB-071

Explore how TRexBio’s TRB-071 CD30 agonist and Lilly-partnered TRB-051 could reshape tissue Treg drug development. Read the analysis.

Read More
Zura Bio advances tibulizumab after exceeding Phase 2 enrollment targets in hidradenitis suppurativa and systemic sclerosis studies. Representative image.
Pharma & Biotech

Zura Bio bets on dual IL-17 and BAFF inhibition across three immune-mediated disease

Explore how Zura Bio’s expanded tibulizumab Phase 2 program could change treatment development in HS and systemic sclerosis.

Read More
Representative image of biosimilar development and biologics manufacturing for autoimmune disease treatment, highlighting the Polpharma Biologics and Tuteur licensing deal to expand affordable therapy access across Latin America.
Pharma & Biotech

Can Polpharma Biologics and Tuteur improve access to autoimmune disease biologics in Latin America?

LATAM autoimmune care needs cheaper biologics. Polpharma Biologics and Tuteur are betting a biosimilar deal can shift access.

Read More
Pharma & Biotech

Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut

Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.

Read More
Pharma & Biotech

Accro Bioscience’s $50m round signals growing interest in targeted IBD immunology

IBD needs safer oral options. Accro’s $50 million raise puts RIPK2 inhibition closer to a decisive clinical test.

Read More
Representative image of circular RNA-based in vivo CAR-T research in a biotechnology laboratory, highlighting Therorna’s TI-0032 program and the growing push to make cell therapy more scalable for autoimmune disease treatment.
Pharma & Biotech

Could Therorna’s circRNA in vivo CAR-T platform change autoimmune disease treatment?

CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.

Read More
Representative image: Mabwell’s 9MW5211 FDA clearance highlights growing clinical interest in first-in-class antibody therapies for inflammatory bowel disease, as biotech developers target pathogenic immune cells to reshape autoimmune disease treatment.
Pharma & Biotech

Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?

Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.

Read More
Representative image of advanced autoimmune drug research, reflecting UCB’s proposed acquisition of Candid Therapeutics and the rising focus on T-cell engager therapies.
Pharma & Biotech

Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?

UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.

Read More
Pharma & Biotech

Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?

Discover how FT839’s conditioning-free CAR T platform could reshape cancer and autoimmune treatment pathways. Read the full analysis now.

Read More